RSS Alerts

Share

More services

Related Links

Related Stories

  • Prostate cancer drug, abiraterone, shows impressive new research results
    Prostate cancer has overtaken lung cancer to become the most common cancer in men, affecting more than 35,000 men every year in the UK. Now, new UK research has confirmed that the cancer drug abiraterone provides a significant benefit for up to two-thirds of men with advanced and aggressive prostate cancer, according to a study published recently in the Journal of Clinical Oncology.
  • Wandering breast cancer cells can stay dormant for decades
    A provocative new theory – that breast cancer cells can self-seed by wandering off around the body and returning to the primary tumour or can stay in the body for several decades after the disease seems to be cured before growing or seeding in other organs – could pave the way for new therapies to destroy the wandering cells that have escaped initial treatment.
  • New drug blocks common cancer pathway
    Scientists have developed a new drug that can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics recently.
  • Catching up on Circulating Tumor Cell Technology
    Circulating tumor cells (CTCs) are cells that ‘escape’ from primary tumor cells and migrate into the bloodstream, where they circulate through the body. CTCs were first identified in the 1980s as cells that had the morphology of tumor cells but were found in the blood. Over the past two decades technological innovations have eased the detection and analysis of CTCs. The resulting investigations of CTCs are an important area of clinical research because they are demonstrating that CTCs have potential clinical value as warning signals of cancer progression.
  • Horizon Discovery and Fox Chase Cancer Center announce collaboration to apply rAAV gene targeting in mouse embryonic stem cells and research into EGFR-therapy resistance.
    Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has announced that it has entered into a 3-year collaboration with the Fox Chase Cancer Center (Fox Chase). The focus of the collaboration is to apply rAAV gene targeting in mouse embryonic stem (ES) cells, and for the discovery of genes involved in resistance to EGFR-targeted therapies in human cancer, such as PI3K.

Top 5 Stories

News

New drug targeting cancer weakness shows great promise

27 July 2009

Scientists at The Institute of Cancer Research and The Royal Marsden Hospital, working with pharmaceutical company AstraZeneca, have completed a Phase I clinical trial demonstrating the promise of a new type of cancer treatment.

The results were announced recently in The New England Journal of Medicine. Patients with inherited forms of advanced breast, ovarian and prostate cancers – caused by mutations in the BRCA1 and BRCA2 genes – were treated with the new drug olaparib (a PARP inhibitor). In more than half of the patients, tumours shrank or stabilized. One of the first patients to be given the treatment is still in remission after two years.

Dr Johann de Bono, one of the Institute of Cancer Research (ICR) scientists who led the AstraZeneca/KuDOS-sponsored Phase I trial held at The Royal Marsden and the Netherlands Cancer Institute, said the positive results confirmed olaparib should be taken into larger patient trials, adding: ‘It’s giving patients who have already tried many conventional treatments long periods of remission, free from the symptoms of cancer or major side-effects’.

The concept behind this new approach is called ‘synthetic lethality’, in which the treatment works in combination with a patient’s own specific molecular defect. Normal cells have several different ways of repairing damage to their DNA; however, BRCA tumours lack one of these pathways. The drug olaparib blocks a different pathway involving the enzyme PARP, and normal cells can recover from this drug because they can use the BRCA genes. When the drug is applied to BRCA tumours, however, they have no way of repairing their DNA, so they simply die. This is why the drug is so effective at killing cancer cells but normal cells seem to be unaffected.

Mutations in the BRCA1 or BRCA2 genes are thought to be responsible for approximately five per cent of breast and ovarian cancers and approximately one to two per cent of early-onset prostate cancers. Women with a BRCA mutation have an up to 85 per cent risk of developing breast cancer and an up to 60 per cent risk of developing ovarian cancer during their lifetime. Men with a BRCA mutation have an up to 15 per cent lifetime risk of prostate cancer. These patients are at high risk of cancer because the genetic fault weakens their cells’ ability to repair any DNA damage.

Cancer cells with the BRCA1 or BRCA2 mutations were the first discovered to be sensitive to PARP inhibitors, but there is evidence that olaparib might be effective in other cancers with different defects in the repair of DNA. These cancers could include some non-inherited breast and prostate cancers and up to half of the most common type of ovarian cancer.

 

This article is featured in:
Drug Trials

 

Comment on this article

You must be registered and logged in to leave a comment about this article.

Copyright © 2012
Elsevier Ltd. All rights reserved.
Terms & Conditions | Privacy | Website Design Working with water